28165004 |
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Tan, S,
Gao, GF,
Tong, Z,
Wong, G,
Shi, Y,
Qi, J,
Zhang, H,
Liu, WJ,
Chai, Y,
Wang, Z,
Song, H,
Gao, S,
Yan, J,
Zhu, X,
Yang, F,
Wang, Q
|
Nat Commun |
2017 |
29863979 |
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Gao, B,
Lewis, KD,
Babiker, HM,
Papadopoulos, KP,
Brana, I,
Migden, MR,
Dunn, LA,
Yancopoulos, GD,
Moreno, V,
Rabinowits, G,
Schadendorf, D,
Niu, J,
Lim, AM,
Gil-Martin, M,
Seebach, F,
Hernandez-Aya, L,
Hughes, BGM,
Guminski, A,
Chung, CH,
Khushalani, NI,
Lowy, I,
Modi, B,
Rischin, D,
Li, J,
Johnson, ML,
Schmults, CD,
Stankevich, E,
Mathias, M,
Booth, J,
Thai, AA,
Homsi, J,
Mohan, K,
Hauschild, A,
Fury, MG,
Chang, ALS,
Owonikoko, TK,
Li, S
|
N. Engl. J. Med. |
2018 |
28265006 |
Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Murphy, A,
D'Orvilliers, A,
Woodruff, A,
Garnova, E,
Kantrowitz, J,
Hermann, A,
Rafique, A,
Skokos, D,
Mohrs, M,
MacDonald, D,
Wu, Q,
Huang, T,
Potocky, T,
Liu, M,
Thurston, G,
Hong, S,
Popke, J,
Poueymirou, W,
Allbritton, O,
Olson, W,
Ioffe, E,
Waite, J,
Lowy, I,
Martin, J,
Lai, V,
Burova, E
|
Mol. Cancer Ther. |
2017 |